These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 7903524)

  • 1. Cathepsin-D and c-erb-B 2 have an additive prognostic value for breast cancer patients.
    Scorilas A; Yotis J; Gouriotis D; Keramopoulos A; Ampela K; Trangas T; Talieri M
    Anticancer Res; 1993; 13(5C):1895-900. PubMed ID: 7903524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cathepsin D assay in primary breast cancer and lymph nodes: relationship with c-myc, c-erb-B-2 and int-2 oncogene amplification and node invasiveness.
    Brouillet JP; Theillet C; Maudelonde T; Defrenne A; Simony-Lafontaine J; Sertour J; Pujol H; Jeanteur P; Rochefort H
    Eur J Cancer; 1990 Apr; 26(4):437-41. PubMed ID: 2141510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of c-myc amplification and overexpression in breast cancer patients: evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathological characteristics using univariate and multivariate analysis.
    Scorilas A; Trangas T; Yotis J; Pateras C; Talieri M
    Br J Cancer; 1999 Dec; 81(8):1385-91. PubMed ID: 10604737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. c-erbB-2 overexpression may be used as an independent prognostic factor for breast cancer patients.
    Scorilas A; Yotis J; Stravolemos K; Gouriotis D; Keramopoulos A; Ampela K; Talieri M; Trangas T
    Anticancer Res; 1995; 15(4):1543-7. PubMed ID: 7654043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Amplification of c-myc and c-erbbeta-2(HER-2/neu) in breast cancer without axillary lymph node metastasis: correlation with other prognostic parameters].
    Lizard-Nacol S; Arnould L; Riedinger JM; Arnal M; Collin F; Guerrin J
    Bull Cancer; 1994 Sep; 81(9):780-4. PubMed ID: 7703567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Estrogens, cathepsin D and metastasis in cancers of the breast and ovary: invasion or proliferation?].
    Rochefort H
    C R Seances Soc Biol Fil; 1998; 192(2):241-51. PubMed ID: 9841098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer.
    Thorpe SM; Rochefort H; Garcia M; Freiss G; Christensen IJ; Khalaf S; Paolucci F; Pau B; Rasmussen BB; Rose C
    Cancer Res; 1989 Nov; 49(21):6008-14. PubMed ID: 2790815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer.
    Berns EM; Klijn JG; van Putten WL; van Staveren IL; Portengen H; Foekens JA
    Cancer Res; 1992 Mar; 52(5):1107-13. PubMed ID: 1737370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour epidermal growth factor receptor, erbB-2 and cathepsin D in node-negative invasive breast cancer: their impact on the selection of patients for systemic adjuvant therapy.
    Tonkin KS; McKay JW; Stitt LW; Tokmakejian S; Haines DS
    Cancer Prev Control; 1999 Apr; 3(2):131-6. PubMed ID: 10474760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoenzymatic assay of Mr 52,000 cathepsin D in 182 breast cancer cytosols: low correlation with other prognostic parameters.
    Maudelonde T; Khalaf S; Garcia M; Freiss G; Duporte J; Benatia M; Rogier H; Paolucci F; Simony J; Pujol H
    Cancer Res; 1988 Jan; 48(2):462-6. PubMed ID: 3275497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of c-erbB-2 and cathepsin-D for Greek breast cancer patients using univariate and multivariate analysis.
    Scorilas A; Yotis J; Pateras C; Trangas T; Talieri M
    Clin Cancer Res; 1999 Apr; 5(4):815-21. PubMed ID: 10213217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
    Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
    Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors.
    Jahkola T; Toivonen T; von Smitten K; Virtanen I; Wasenius VM; Blomqvist C
    Br J Cancer; 1999 Apr; 80(1-2):167-74. PubMed ID: 10389993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cathepsin D in primary breast cancer in correlation with various prognostic factors].
    Rempen A; Caffier H
    Geburtshilfe Frauenheilkd; 1991 Apr; 51(4):272-5. PubMed ID: 1650323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations.
    Gaffey MJ; Frierson HF; Williams ME
    Mod Pathol; 1993 Nov; 6(6):654-9. PubMed ID: 7905628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer.
    Champème MH; Bièche I; Hacène K; Lidereau R
    Mod Pathol; 1994 Dec; 7(9):900-5. PubMed ID: 7892157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cathepsin D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays.
    Kute TE; Shao ZM; Sugg NK; Long RT; Russell GB; Case LD
    Cancer Res; 1992 Oct; 52(19):5198-203. PubMed ID: 1394123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical demonstration of c-erb B-2 oncoprotein expression in female breast cancer and its prognostic significance.
    Tervahauta A; Eskelinen M; Syrjänen S; Lipponen P; Pajarinen P; Syrjänen K
    Anticancer Res; 1991; 11(5):1677-81. PubMed ID: 1685075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study.
    Kristensen GB; Holm R; Abeler VM; Tropé CG
    Cancer; 1996 Aug; 78(3):433-40. PubMed ID: 8697388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological and clinical significance of cathepsin D in breast cancer metastasis.
    Garcia M; Platet N; Liaudet E; Laurent V; Derocq D; Brouillet JP; Rochefort H
    Stem Cells; 1996 Nov; 14(6):642-50. PubMed ID: 8948022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.